MedTrace Logo

Nasal Decolonization for Orthopedic Trauma Patients

NCT04146116 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2023-06-28

Study results available
· View outcomes & findings →

Summary

Many surgical site infections are caused by bacteria that is transferred from a patient's nose to their open surgical wound. Some small studies have shown that putting povidone-iodine in a patient's nose reduces this risk. This study aims to evaluate the real-world effectiveness of nasal povidone-iodine (PROFEND®) in a group of 50 patients at the University of Iowa.

Conditions

  • Surgical Site Infection

Interventions

DRUG

intranasal povidone-iodine

povidone-iodine USP, 10% w/w antiseptic

Sponsors & Collaborators

  • Professional Disposables International, Inc.

    collaborator INDUSTRY

  • University of Iowa

    lead OTHER

Principal Investigators

  • Marin L Schweizer, PhD · University of Iowa

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-19
Primary Completion
2021-06-08
Completion
2021-06-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04146116 on ClinicalTrials.gov